Advances in cutaneous melanoma

Clinical and Translational Oncology

Volumn 14, Issue 5, 2012, Pages 325-332

  Espinosa, Enrique ^a,b   Berrocal, Alfonso ^b   López Martín, José Antonio ^b   González Cao, María ^b   Cerezuela, Pablo ^b   Ignacio Mayordomo, José ^b   Martín Algarra, Salvador ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Grupo Español de Melanoma GEM   (Spain)

Author keywords

BRAF mutation; Interferon; Ipilimumab; Melanoma; Vemurafenb

Indexed keywords

ALBUMIN; ALPHA2B INTERFERON; B RAF KINASE INHIBITOR; CANCER VACCINE; CARBOPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DACARBAZINE; FOTEMUSTINE; GP100 VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; GSK 118436; IMATINIB; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; MAGE A3 VACCINE; MONOCLONAL ANTIBODY; OX44 ANTIBODY; PACLITAXEL; PD 1 ANTIBODY; PEGINTERFERON; PEPTIDE VACCINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; TEMOZOLOMIDE; TICILIMUMAB; TRAMETINIB; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB;

ADVANCED CANCER; ANEMIA; ARTHRALGIA; ARTICLE; BRAF GENE; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CDKN2A GENE; CELL CYCLE PROGRESSION; CUTANEOUS MELANOMA; DEPRESSION; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; GENE LOCUS; GENE MUTATION; GNA11 GENE; GNAQ GENE; HUMAN; HYPOTHYROIDISM; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MOLECULAR BIOLOGY; NAUSEA; NRAS GENE; ONCOGENE; ONCOGENE C KIT; OVERALL SURVIVAL; PHOTOSENSITIVITY; PROTEIN DEGRADATION; SIDE EFFECT; SKIN MANIFESTATION; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

DISEASE MANAGEMENT; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 84860712037     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0804-4     Document Type: Article

References (62)

1. MacKie RM, Hauschild A, Eggermont AM (2009) Epidemiology of invasive cutaneous melanoma. Ann Oncol 20[Suppl 6]:vi1-7
2. Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classifi cation. J Clin Oncol 27:6199-6206
3. Lin WM, Baker AC, Beroukhim R et al (2008) Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res 68:664-673 (Pubitemid 351206741)
4. Edlundh-Rose E, Egyhazi S, Omholt K et al (2006) NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 16:471-478 (Pubitemid 44934704)
5. Gorden A, Osman I, Gai W et al (2003) Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 63:3955-3957 (Pubitemid 36917911)
6. Maldonado JL, Fridlyand J, Patel H et al (2003) Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95:1878-1890
7. Handolias D, Salemi R, Murray W et al (2010) Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res 23:210-215
8. Harbour JW, Onken MD, Roberson ED et al (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330:1410-1413
9. Romano E, Scordo M, Dusza SW et al (2010) Site and timing of fi rst relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol 28:3042-3047
10. Turner RM, Bell KJ, Morton RL et al (2011) Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma. J Clin Oncol 29:4641-4646
11. Wheatley K, Ives N, Hancock B et al (2003) Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefi t? A meta-analysis of the randomised trials. Cancer Treat Rev 29:241-252 (Pubitemid 37069655)
12. Mocellin S, Pasquali S, Rossi CR, Nitti D (2010) Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 102:493-501
13. Pirard D, Heenen M, Melot C, Vereecken P (2004) Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis. Dermatology 208:43-48 (Pubitemid 38142333)
14. Hauschild A, Weichenthal M, Rass K et al (2010) Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >=1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. J Clin Oncol 28:841-846
15. Eggermont AM, Suciu S, Santinami M et al (2008) Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: fi nal results of EORTC 18991, a randomised phase III trial. Lancet 372:117-126 (Pubitemid 351952257)
16. Eggermont AM, Suciu S, Testori A et al (2012) Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 48:218-225
17. Eggermont AM, Suciu S, MacKie R et al (2005) Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366:1189-1196 (Pubitemid 41393597)
18. Lawson D, Lee S, Tarhini AA et al (2010) E4697: phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma. In: Proc Am Soc Clin Oncol abs 8504
19. Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351:998-1012
20. Lee ML, Tomsu K, Von Eschen KB (2000) Duration of survival for disseminated malignant melanoma: results of a meta-analysis. Melanoma Res 10:81-92 (Pubitemid 30127833)
21. Patel PM, Suciu S, Mortier L et al (2011) Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: fi nal results of a randomised phase III study (EORTC 18032). Eur J Cancer 47:1476-1483
22. Avril MF, Aamdal S, Grob JJ et al (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22:1118-1125 (Pubitemid 41095046)
23. Hersh EM, O'Day SJ, Ribas A et al (2010) A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer 116:155-163
24. Atkins MB, Hsu J, Lee S et al (2008) Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 26:5748-5754
25. Kottschade LA, Suman VJ, Amatruda T 3rd et al (2011) A phase II trial of nab-paclitaxel (ABI- 007) and carboplatin in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group Study, N057E(1). Cancer 117: 1704-1710
26. Robert C, Ghiringhelli F (2009) What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist 14:848-861
27. Peggs KS, Quezada SA, Korman AJ, Allison JP (2006) Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 18:206-213 (Pubitemid 43327304)
28. Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723
29. Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526
30. Wolchok JD, Hoos A, O'Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412-7420
31. Ribas A (2010) Clinical development of the anti- CTLA-4 antibody tremelimumab. Semin Oncol 37:450-454
32. Tarhini AA (2010) Phase II evaluation of tremelimumab (Treme) combined with high-dose interferon alpha-2b (HDI) for metastatic melanoma. In: Proc Am Soc Clin Oncol abs 8524
33. Eggermont AM, Robert C (2011) New drugs in melanoma: it's a whole new world. Eur J Cancer 47:2150-2157
34. Brahmer JR, Drake CG, Wollner I et al (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167-3175
35. Lee JT, Li L, Brafford PA et al (2010) PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res 23:820-827
36. Yang H, Higgins B, Kolinsky K et al (2010) RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 70:5518-5527
37. Ribas A (2010) BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutationpositive metastatic melanoma. In Proc Am Soc Clin Oncol abs 8509
38. Sosman JA, Kim K, Schuchter L et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Egl J Med 366:707-714
39. Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516
40. Kefford R (2010) Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. In Proc Am Soc Clin Oncol abs 8503
41. Wagle N, Emery C, Berger MF et al (2011) Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profi ling. J Clin Oncol 29:3085-3096
42. Nazarian R, Shi H, Wang Q et al (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-977
43. Johannessen CM, Boehm JS, Kim SY et al (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968-972
44. Poulikakos PI, Persaud Y, Janakiraman M et al (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480:387-390
45. Villanueva J, Vultur A, Lee JT et al (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18:683-695
46. Yancovitz M, Litterman A, Yoon J et al (2012) Intra- and inter-tumor heterogeneity of BRAF mutations in primary and metastatic melanoma. PLoS One 7:e29336
47. Infante J (2011) Phase I/II study to assess safety, pharmacokinetics, and effi cacy of the oral MEK 1/2 inhibitor GSK1120212 dosed in combination with the oral BRAF inhibitor GSK2118436. In Proc Am Soc Clin Oncol abs 8503
48. Beadling C, Jacobson-Dunlop E, Hodi FS et al (2008) KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 14:6821-6828
49. Guo J, Si L, Kong Y et al (2011) Phase II, openlabel, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplifi cation. J Clin Oncol 29:2904-2909
50. Carvajal RD, Antonescu CR, Wolchok JD et al (2011) KIT as a therapeutic target in metastatic melanoma. JAMA 305:2327-2334
51. Creagan ET, Dalton RJ, Ahmann DL et al (1995) Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 13:2776-2783
52. Kirkwood JM, Strawderman MH, Ernstoff MS et al (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17 (Pubitemid 26019991)
53. Kirkwood JM, Ibrahim JG, Sondak VK et al (2000) High- and low-dose interferon alfa-2b in high-risk melanoma: fi rst analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18:2444-2458 (Pubitemid 30415832)
54. Kirkwood JM, Ibrahim JG, Sosman JA et al (2001) High-dose interferon alfa-2b signifi cantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19:2370-2380 (Pubitemid 32391207)
55. Agarwala SS (2011) Randomized phase III trial of high-dose interferon alfa-2b for 4 weeks induction only in patients with intermediate and high-risk melanoma. In Proc Am Soc Clin Oncol abs 8505
56. Hauschild A, Weichenthal M, Rass K et al (2009) Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modifi ed high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma. J Clin Oncol 27:3496-3502
57. Hansson J, Aamdal S, Bastholt L et al (2011) Two different durations of adjuvant therapy with intermediate- dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol 12:144-152
58. Pehamberger H, Soyer HP, Steiner A et al (1998) Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 16:1425-1429 (Pubitemid 28175761)
59. Grob JJ, Dreno B, de la Salmoniere P et al (1998) Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 351:1905-1910 (Pubitemid 28297445)
60. Hancock BW, Wheatley K, Harris S et al (2004) Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 22:53-61 (Pubitemid 41095114)
61. Garbe C, Radny P, Linse R et al (2008) Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol 19:1195-1201 (Pubitemid 351796347)
62. Cascinelli N, Belli F, MacKie RM et al (2001) Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 358:866-869 (Pubitemid 32900567)